{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:12:47Z","timestamp":1790482367604,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Current epidemiologic evidence on the association between antihypertensive drugs and keratinocyte carcinoma (KC) risk is inconsistent. We sought to quantify this association by meta\u2010analysis of observational studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically reviewed observational studies published through August 2016 and reported the KC risk (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) associated with antihypertensive drugs, including diuretics, angiotensin\u2010converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta\u2010adrenergic blocking agents (\u03b2\u2010blockers), and calcium channel blockers (CCBs). Random\u2010effects meta\u2010analysis was used to estimate the odds ratio (OR) with 95% confidence interval (CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten eligible studies were included. Compared with nonuse, diuretic use was significantly associated with increased risk of both BCC (OR, 1.10; 95% CI, 1.01\u20101.20) and SCC (OR, 1.40; 95% CI, 1.19\u20101.66). Use of \u03b2\u2010blockers or CCBs was associated with increased risk of BCC (but not SCC); the OR with \u03b2\u2010blockers was 1.09 (95% CI, 1.04\u20101.15) and with CCBs was 1.15 (95% CI, 1.09\u20101.21). Use of ACE inhibitors or ARBs was associated with decreased risk of both BCC (OR, 0.53; 95% CI, 0.39\u20100.71) and SCC (OR, 0.58; 95% CI, 0.42\u20100.80) in high\u2010risk individuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Current evidence indicates that use of diuretics might be associated with increased risk of KC, while ACE inhibitors or ARBs might be associated with decreased risk in high\u2010risk individuals. \u03b2\u2010blockers or CCBs might be positively associated with BCC risk. Further postmarketing surveillance studies and investigations to clarify the possible underlying mechanisms are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4384","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T16:04:41Z","timestamp":1515600281000},"page":"279-288","source":"Crossref","is-referenced-by-count":32,"title":["Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta\u2010analysis of observational studies"],"prefix":"10.1002","volume":"27","author":[{"given":"Huilin","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Peking University Third Hospital  Beijing China"},{"name":"Department of Epidemiology, Richard M. Fairbanks School of Public Health Indiana University  Indianapolis IN USA"},{"name":"Center for Pharmacoepidemiology, Richard M. Fairbanks School of Public Health Indiana University  Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Fu","sequence":"additional","affiliation":[{"name":"School of Public Health The University of Texas Health Science Center at Houston  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-359X","authenticated-orcid":false,"given":"Suodi","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2097-7332","authenticated-orcid":false,"given":"Yiqing","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Richard M. Fairbanks School of Public Health Indiana University  Indianapolis IN USA"},{"name":"Center for Pharmacoepidemiology, Richard M. Fairbanks School of Public Health Indiana University  Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam M.","family":"Asgari","sequence":"additional","affiliation":[{"name":"Department of Dermatology Massachusetts General Hospital  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-7092","authenticated-orcid":false,"given":"Jiali","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Richard M. Fairbanks School of Public Health Indiana University  Indianapolis IN USA"},{"name":"Center for Pharmacoepidemiology, Richard M. Fairbanks School of Public Health Indiana University  Indianapolis IN USA"},{"name":"Melvin and Bren Simon Cancer Center Indiana University  Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1187"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099674"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1997.tb01000.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0821"},{"issue":"2","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archderm.1995.01690140041006","article-title":"Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma","volume":"131","author":"Gallagher RP","year":"1995","journal-title":"Arch Dermatol"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690140048007"},{"issue":"3","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1742-1241.1998.tb11592.x","article-title":"A comparison of risk factors for malignant melanoma, squamous cell carcinoma and basal cell carcinoma in the UK","volume":"52","author":"Lear JT","year":"1998","journal-title":"Int J Clin Pract"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11085.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2016.05.006"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14935"},{"key":"e_1_2_9_12_1","unstructured":"ShieldsKM.Drug\u2010induced photosensitivity 2004. Available at:http:\/\/www.wellnesspharmacy.net\/photosensitivity.pdf[December 25 2016]."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225050-00004"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604686"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12921"},{"issue":"8","key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1158\/1055-9965.EPI-14-0251","article-title":"Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort","volume":"23","author":"McDonald E","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.2754"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0652"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn262"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_9_21_1","unstructured":"GA Wells BS DO'Connell JPeterson VWelch MLosos PTugwell.The Newcastle\u2010Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses. Available at:http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp[December 25 2016]"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.08.010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11081.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.33"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP73439"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.04.024"},{"issue":"4","key":"e_1_2_9_28_1","first-page":"a3","article-title":"Melanoma and non\u2010melanoma skin cancer associated with antihypertensive drugs: a report from the Research on Adverse Drug Events and Reports project B","volume":"56","author":"Nardone KAS","year":"2015","journal-title":"Australasian Journal of Dermatology"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0487-9"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(98)00237-9"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1011-1344(01)00198-1"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70213-X"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.03.027"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys146"},{"key":"e_1_2_9_35_1","first-page":"12","article-title":"Photosensitivity: light, sun and pharmacy","volume":"16","author":"Zammit ML","year":"2010","journal-title":"Journal of the Malta College of Pharmacy"},{"issue":"2","key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/02841860310022346","article-title":"Angiotensin converting enzyme inhibitors for cancer treatment?","volume":"43","author":"Lindberg H","year":"2004","journal-title":"Acta Oncol"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T01:39:56Z","timestamp":1695692396000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/pds.4384"],"URL":"https:\/\/doi.org\/10.1002\/pds.4384","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,10]]}}}